Holly Barwick
Clinical Trial Administrator
Holly joined Oxford Population Health in October 2024 and is working as part of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) on the ASCEND PLUS trial. ASCEND PLUS is a randomised study investigating if oral semaglutide (GLP-1-RA) reduces the risk of cardiovascular disease for patients with Type 2 diabetes without established cardiovascular disease.
Holly graduated from Swansea University in 2022 with a Bachelor of Science degree in Biology, having completed an incorporated Year in Industry placement within the university. Following university, she began working in clinical trial project management within contract research organisations.
Her past experience working in project management and laboratory project management of clinical trials has covered a range of drugs and indications in Phase 1 trials, through to Phase 3 trials, with particular focus on rare and orphan diseases.